On Friday, Shares of Sirius XM Holdings Inc. (NASDAQ:SIRI), lost -0.52% to $3.86.
Sirius XM, declared that host David Webb will attend the Republican National Committee summer meeting in Cleveland, offering candidates for the Republican nomination a unique platform to reflect on their candidacy and share personal anecdotes of interest to American voters.
Webb’s interviews – conducted in a five-question format – will profile the candidates’ life journeys, in addition to their personal interests outside of politics. The interviews will air August 6th on Patriot, SiriusXM’s conservative talk channel (125), and the non-partisan POTUS channel (124).
Sirius XM Holdings Inc., through its auxiliaries, provides satellite radio services in the United States. The company broadcasts music plus sports, entertainment, comedy, talk, news, traffic, and weather programs, counting various music genres ranging from rock, pop and hip-hop to country, dance, jazz, Latin, and classical; live play-by-play sports from principal leagues and colleges; multitude of talk and entertainment channels for various audiences; national, international, and financial news; and local traffic reports for 22 metropolitan markets.
Shares of American International Group, Inc. (NYSE:AIG), declined -0.17% to $64.05, during its last trading session.
American International Group, declared the final results as of 11:59 p.m., New York City time, on July 16, 2015, the expiration date, of its formerly declared maximum cash tender offer for up to $3.3 billion (U.S. Dollar equivalent) aggregate principal amount of the notes and debentures issued or guaranteed by AIG, following its offer to purchase dated June 18, 2015. The complete terms of the tender offer are set forth in the offer to purchase and the related letter of transmittal.
AIG has accepted all notes and debentures validly tendered and not withdrawn.
American International Group, Inc. provides insurance products and services for commercial, institutional, and individual customers in the United States, the Asia Pacific, and internationally.
Finally, Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM), ended its last trade with 2.27% gain, and closed at $1.35.
Peregrine Pharmaceuticals, declared financial results for the fourth quarter and the fiscal year (FY) 2015 ended April 30, 2015 and offered an update on its advancing clinical pipeline and other corporate developments.
Clinical Highlights:
- Continued progress enrolling ongoing SUNRISE clinical trial in non-small cell lung cancer (NSCLC); study remains on plan to complete enrollment by end of calendar 2015
- Peregrine declared plans to expand the bavituximab clinical development program to comprise a Phase II trial to evaluate the combination of bavituximab and Opdivo® (nivolumab), an anti-PD-1 antibody, in NSCLC, and a Phase II/III trial to evaluate bavituximab with chemotherapy combinations in HER2-negative metastatic breast cancer. These trials are predictable to be initiated during the second half of 2015.
- Phase I study results from an investigator-sponsored trial evaluating bavituximab plus paclitaxel in patients with HER2-negative metastatic breast cancer were published in the peer-reviewed journal, Cancer Medicine. Findings showed that the combination produced an objective tumor response in 85% of evaluable patients, with 15% of patients achieving a complete response, measured in accordance with published Response Evaluation Criteria In Solid Tumors (RECIST).
- Data presented at the 2015 ASCO annual meeting from a Phase I/II study of bavituximab and sorafenib in advanced hepatocellular carcinoma (HCC) demonstrated that the treatment combination induced multiple signs of immune activation with a corresponding reduction of T-regulatory cells in the tumor environment. The treatment was well-tolerated with no indications of autoimmune adverse events that have been seen with other checkpoint immunotherapies.
Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the research and development of novel monoclonal antibodies for the treatment and diagnosis of cancer in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
